Effectiveness of dialectical behavior therapy for fatigue, depression, anxiety, stress and quality of life of patients with Multiple Sclerosis

Effectiveness of dialectical behavior therapy for fatigue, depression, anxiety, stress and quality of life of patients with Multiple Sclerosis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210720051948N1

Enrollment

Registered

2021-09-24

Start date

2016-08-22

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: After pretest, term of dialectical behavior therapy was 8 sessions with one session per week in the test group (15 individuals). Follow-up assessment took place in

Eligibility

Sex/Gender

All

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: Having MS diagnostic criteria based on McDonald's criteria being at the age group of between 25 and 40 years Having no severe attack and recurrence of the disease Scored above 14 in depression scale (DASS-21) Scored above 25 in anxiety scale (DASS-21) Scored above 19 in stress scale (DASS-21) being able to communicate and collaborate Having interest in the study as well as inclination to participate in it

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depression, Anxiety, Stress. Timepoint: Prior to the study(before starting treatment), 60 days(right after ending the treatment) and finally 30 days later (after ending the treatment in follow-up stage). Method of measurement: Depression, Anxiety and Stress Scale (DASS-21).;Quality of life. Timepoint: Prior to the study(before starting treatment), 60 days(right after ending the treatment) and finally 30 days later (after ending the treatment in follow-up stage). Method of measurement: Quality of life questionnaire (MSQOL-54).;Fatigue. Timepoint: Prior to the study(before starting treatment), 60 days(right after ending the treatment) and finally 30 days later (after ending the treatment in follow-up stage). Method of measurement: Fatigue Severity Scale (FSS).	—

Measure

Time frame

Depression, Anxiety, Stress. Timepoint: Prior to the study(before starting treatment), 60 days(right after ending the treatment) and finally 30 days later (after ending the treatment in follow-up stage). Method of measurement: Depression, Anxiety and Stress Scale (DASS-21).;Quality of life. Timepoint: Prior to the study(before starting treatment), 60 days(right after ending the treatment) and finally 30 days later (after ending the treatment in follow-up stage). Method of measurement: Quality of life questionnaire (MSQOL-54).;Fatigue. Timepoint: Prior to the study(before starting treatment), 60 days(right after ending the treatment) and finally 30 days later (after ending the treatment in follow-up stage). Method of measurement: Fatigue Severity Scale (FSS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Nazari

Islamic Azad University

fatemehnazarik1991@gmai.com0098314226425

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026